Evgen Pharma (GB:TCF) has released an update.
TheraCryf plc, a clinical stage drug development company specializing in oncology and neuropsychiatry, has announced a Research and Development event to discuss updates on its clinical program for glioblastoma and preclinical neuropsychiatry programs. The event will showcase the positive effects of their drug SFX-01 combined with radiation on glioblastoma cells and will include insights from internal and external experts. It is open to stakeholders and features both in-person and virtual attendance options.
For further insights into GB:TCF stock, check out TipRanks’ Stock Analysis page.
